Baseline characteristics according to treatment arm
| . | Overall N = 332 . | RD n = 161 . | IRD n = 171 . |
|---|---|---|---|
| Age, median (range), y | 58 (32-67) | 58 (36-67) | 59 (32-67) |
| Male sex, n (%) | 181 (54%) | 94 (58%) | 87 (51%) |
| ISS (%) | |||
| I | 136 (40.9%) | 69 (42.8%) | 67 (39.1%) |
| II | 116 (34.9%) | 49 (30.459%) | 67 (39.1%) |
| III | 75 (22.5%) | 39 (24.259%) | 36 (21%) |
| High-risk cytogenetics∗, n (%) | 64 (22.5%) | 33 (24.6%) | 31 (20.6%) |
| Plasmacytomas†, n (%) | 67 (20.1%) | 30 (18.6%) | 37 (21.6%) |
| Depth of response | |||
| sCR/CR, n (%) | 231 (69.5%) | 105 (65%) | 126 (73%) |
| Negative MRD‡, n (%) | 184 (55.4%) | 82 (50.9%) | 101 (59.6%) |
| . | Overall N = 332 . | RD n = 161 . | IRD n = 171 . |
|---|---|---|---|
| Age, median (range), y | 58 (32-67) | 58 (36-67) | 59 (32-67) |
| Male sex, n (%) | 181 (54%) | 94 (58%) | 87 (51%) |
| ISS (%) | |||
| I | 136 (40.9%) | 69 (42.8%) | 67 (39.1%) |
| II | 116 (34.9%) | 49 (30.459%) | 67 (39.1%) |
| III | 75 (22.5%) | 39 (24.259%) | 36 (21%) |
| High-risk cytogenetics∗, n (%) | 64 (22.5%) | 33 (24.6%) | 31 (20.6%) |
| Plasmacytomas†, n (%) | 67 (20.1%) | 30 (18.6%) | 37 (21.6%) |
| Depth of response | |||
| sCR/CR, n (%) | 231 (69.5%) | 105 (65%) | 126 (73%) |
| Negative MRD‡, n (%) | 184 (55.4%) | 82 (50.9%) | 101 (59.6%) |